5. References

  1. Rifaximin (Xifaxan®) package insert. Salix Pharmaceuticals, October 2019.
  2. Shayto RH, Abou Mrad R, Sharara AI. Use of rifaximin in gastrointestinal and liver diseases. World J Gastroenterol. 2016; 22(29): 6638-51.
  3. DuPont HL, Ericsson CD, Mathewson JJ, et al. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea. Digestion. 1998;59:708-14.
  4. DuPont HL, Jiang ZD, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med. 2005;142:805-12.
  5. DuPont HL, Jiang ZD, Ericsson CD, et al. Rifaximin versus ciprofloxacin for the treatment of travelers’ diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis. 2001;33:1807-15.
  6. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc; 2020. Available at: http://www.clinicalpharmacology.com. Accessed June 23, 2020.
  7. Rifaximin (Drug Evaluation). IBM Micromedex® DRUGDEX® (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: http://www.micromedexsolutions.com.libproxy.uthscsa.edu/  (cited: June 23, 2020). 
  8. Lexicomp Inc., Hudson, Ohio: Wolters Kluwer Clinical Drug Information, Inc.; 2022; Accessed June 3, 2022.
  9. Pakyz AL. Rifaximin: a new treatment for travelers’ diarrhea. Ann Pharmacother. 2005;39:284-9.
  10. DuPont HL. Travellers’ diarrhoea: contemporary approaches to therapy and prevention. Drugs.  2006;66:303-14.
  11. Okhuysen PC. Current concepts in travelers' diarrhea: epidemiology, antimicrobial resistance and treatment. Curr Opin Infect Dis. 2005;18:522-6.
  12. Layer P, Andresen V. Review article: rifaximin, a minimally absorbed oral antibacterial, for the treatment of travellers' diarrhoea. Aliment Pharmacol Ther. 2010;31(11):1155-64.
  13. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071-81.
  14. Pimentel M, Lembo A, Chey WD, et al. for the TARGET Study Group.  Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22-32.
  15. Gionchetti P, Rizzello F, Ferrieri A, et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci. 1999;44:1220-1.
  16. Prantera C, Lochs H, Campieri M, et al. Antibiotic treatment of Crohn’s disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther. 2006;23:1117-25.
  17. Adachi JA, DuPont HL Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin Infect Dis. 2006;42:541-7.
  18. Taylor DN, McKenzie R, Durbin A, et al. Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clin Infect Dis. 2006;42:1283-8.
  19. Huang DB, DuPont HL. Rifaximin – a novel antimicrobial for enteric infections. J Infect. 2005;50(2):97-106.  
  20. Taylor DN, Bourgeois AL, Ericsson CD, et al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers’ diarrhea. Am J Trop Med Hyg. 2006;74:1060-6.
  21. Frisari L, Viggiano V, Pelagalli M. An open, controlled study of two non-absorbable antibiotics for the oral treatment of paediatric infectious diarrhea.  Curr Med Res Opin. 1997;14:39-45.
  22. Vinci M, Gatto A, Giglio A, et al. Double-blind clinical trial on infectious diarrhea therapy: rifaximin versus placebo. Curr Ther Res. 1984;36:92-9.
  23. Paik YH, Lee KS, Han KH, et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.  Yonsei Med J. 2005;46:399-407.
  24. Mas A, Rodes J, Sunyer L, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol. 2003;38:51-8.
  25. Miglio F, Valpiani D, Rossellini SR, Ferrieri A. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomized trial. Curr Med Res Opin. 1997;13:593-601.
  26. Phongsamran PV, Kim JW, Cupo Abbott J, Rosenblatt A. Pharmacotherapy for hepatic encephalopathy. Drugs. 2010;70(9):1131-48.
  27. Vlachogiannakos J, Viazis N, Vasianopoulou P, et al. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol. 2013;28:450-5.
  28. Hong KS, Kim JS. Rifaximin for the treatment of acute infectious diarrhea. Therap Adv Gastroenterol. 2011;4(4):227-235.
  29. Connor, A. Travelers’ diarrhea, Chapter 2, Yellow Book: Travelers’ Health. Centers for Disease Control and Prevention. 2020.